Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Edmund Potere described in his deposition that Cutter would no longer release Koate from prison plasma.

  • Read more about Edmund Potere described in his deposition that Cutter would no longer release Koate from prison plasma.

Memo from Robert Barden to Dr John Hink recommended accepting an invitation from the warden of Arizona State Prison to establish a plasmapheresis centre there as it represented a "great opportunity for us to produce some low cost plasma."

  • Read more about Memo from Robert Barden to Dr John Hink recommended accepting an invitation from the warden of Arizona State Prison to establish a plasmapheresis centre there as it represented a "great opportunity for us to produce some low cost plasma."

Hyland's policy as of the end of October 1983 was to discontinue the use of prison plasma for the manufacture of coagulation factors. However, "Any intermediate fractions manufactured from plasma pooled [that] week, or in previous weeks, would be processed to final product."

  • Read more about Hyland's policy as of the end of October 1983 was to discontinue the use of prison plasma for the manufacture of coagulation factors. However, "Any intermediate fractions manufactured from plasma pooled [that] week, or in previous weeks, would be processed to final product."

Dr Ojala estimated that prison plasma accounted for approximately 2% of the total plasma collected in the US as of mid 1982 and was obtained from no more than six to eight centres.

  • Read more about Dr Ojala estimated that prison plasma accounted for approximately 2% of the total plasma collected in the US as of mid 1982 and was obtained from no more than six to eight centres.

Hyland and Cutter obtained plasma from plasmapheresis centres located in prisons in the US and used that plasma in the production of factor concentrates.

  • Read more about Hyland and Cutter obtained plasma from plasmapheresis centres located in prisons in the US and used that plasma in the production of factor concentrates.

William Hartin stated that dealing with paid donors increases the likelihood of people from the lower socioeconomic bracket becoming donors.

  • Read more about William Hartin stated that dealing with paid donors increases the likelihood of people from the lower socioeconomic bracket becoming donors.

A memo from Robert Spiller to Dr Harry Meyer criticised the Bureau of Biologics practice of giving advance notice before some inspections.

  • Read more about A memo from Robert Spiller to Dr Harry Meyer criticised the Bureau of Biologics practice of giving advance notice before some inspections.

A memo from Stewart Mueller to W Biles detailed Dr Jones's inspections of Plasma Alliance.

  • Read more about A memo from Stewart Mueller to W Biles detailed Dr Jones's inspections of Plasma Alliance.

Travenol Laboratories implemented a Guidance for Whole Blood and Plasma Processing Log. This was described as akin to the quality assurance plans as part of product licence applications provided to UK authorities.

  • Read more about Travenol Laboratories implemented a Guidance for Whole Blood and Plasma Processing Log. This was described as akin to the quality assurance plans as part of product licence applications provided to UK authorities.

Travenol Laboratories implemented a Guidance for Source Plasma (Human) Label. This was described as akin to the quality assurance plans as part of product licence applications provided to UK authorities.

  • Read more about Travenol Laboratories implemented a Guidance for Source Plasma (Human) Label. This was described as akin to the quality assurance plans as part of product licence applications provided to UK authorities.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 307
  • Page 308
  • Page 309
  • Page 310
  • Current page 311
  • Page 312
  • Page 313
  • Page 314
  • Page 315
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.